Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs SPDR Gold Trust (GLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs SPDR Gold Trust — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.08 (market cap $8.04B), while SPDR Gold Trust trades at $372.91. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals.
| BIO | GLD | |
|---|---|---|
Market Cap | $8.04B | — |
Sector | Health | — |
52-Week High | $339.75 | $495.90 |
52-Week Low | $241.71 | $300.96 |
Enterprise Value | $7.85B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GLD trades at $367.13, down 2.59% amid a bearish technical setup with 19 sell signals versus 2 buys. Support lies at $365 and $363, while resistance is at $370 and $374. Recent news highlights gold's volatility from inflation data and Fed policy shifts, with prices testing key levels after softer CPI provided temporary relief.
The outlook remains cautious as rising yields and dollar strength pressure gold. Near-term direction hinges on Fed rate expectations and geopolitical tensions. Risks include prolonged high rates eroding gold's appeal, while potential inflation spikes or market instability could renew safe-haven demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →
